NGNE — Neurogene Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Neurogene Inc

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$27.10
Market Cap$436M
Float6.0M
Shares Outstanding15.8M
Price/Sales (TTM)583.60
vs. Analyst Target+195.2% to analyst PT
Dividend RateNone
Analyst Target Price$80.00 (7 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$33.3M -$1.8M -$31.5M
2021 N/A -$50.5M -$42.3M -$49.6M
2022 N/A -$55.2M -$3.2M -$52.0M
2023 N/A -$36.3M -$3.3M -$52.3M
2024 $925,000 -$75.1M -$2.3M -$71.9M
2025 N/A -$90.4M -$3.2M -$103M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$22.0M
Sep 2025 N/A -$21.0M
Dec 2025 N/A -$24.7M
Mar 2026 N/A -$30.9M

Ownership & Float

Insider Ownership8.8%
Institutional Ownership110.4%
Short Float62.0%
% of All Funds Holding1.05%
Number of Funds Holding86

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$25.86Near-term / short-term trend
Weekly40-Week SMA$22.48Medium-term trend
Weekly80-Week SMA$20.51Cyclical trend (business cycle)
Weekly200-Week SMA$22.30Secular trend (multi-year)
Monthly10-Month SMA$22.62Near-term monthly trend
Monthly20-Month SMA$21.63Medium-term monthly trend
Monthly40-Month SMA$23.49Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$31.00 resistance 1.06x 5 months ago
$17.30 support 1.29x 6 months ago
$11.80 support 1.40x 12 months ago
$44.00 resistance 3.96x 17 months ago
$50.00 resistance 2.28x 24 months ago

Historical Earnings Reactions (49 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.71% 0.13% 53.06% 36.87% -16.34%
1 Day 8.77% -1.78% 34.69% 482.12% -19.81%
1 Week 22.97% -0.86% 44.90% 1136.31% -30.84%
2 Weeks 18.92% -1.69% 43.75% 925.14% -47.42%
1 Month 23.09% 1.33% 52.08% 836.31% -34.09%

Next earnings: July 31, 2026 (64 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan3.6%58.3%12
Feb-1.9%41.7%12
Mar2.2%41.7%12
Apr-4.8%30.8%13
May0.1%50.0%12
Jun-7.2%41.7%12
Jul-5.5%50.0%12
Aug77.7%83.3%12
Sep-6.5%25.0%12
Oct2.0%41.7%12
Nov0.0%41.7%12
Dec14.7%58.3%12

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.20% 45.0% 576
Tuesday 0.02% 46.0% 633
Wednesday -0.15% 43.7% 630
Thursday 0.21% 46.0% 617
Friday 0.80% 47.3% 615

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 110.4%

Insider Transactions — Smart Summary

Total insider ownership: 8.8%

Founder-led management: Rachel McMinn (Founder, Executive Chair & CEO)

12-Month Insider Activity Summary

Total Filings7
Net Value-$793,629.917
Net Shares Change-31,980
% of Float-0.5%
C-Suite Filings7
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Cvijic Christine Mikail President and CFO -$560,061.713 4 N/A
Cobb Stuart Chief Scientific Officer -$141,445.57 1 N/A
McMinn Rachel Chief Executive Officer -$73,995.065 1 N/A
Jordan Julie Chief Medical Officer -$18,127.57 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-03-30 – 2026-03-30 3 3 -$147,438.617 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-17 Cobb Stuart Chief Scientific Officer -$141,445.57 Transaction at $20.81, now +30.2%
2026-05-07 Cvijic Christine Mikail President and CFO -$300,043.2 Transaction at $31.25, now -13.3%
2026-03-30 Cvijic Christine Mikail President and CFO -$55,315.983 Transaction at $21.62, now +25.3%
2026-03-17 Cvijic Christine Mikail President and CFO -$84,176.45 Transaction at $20.81, now +30.2%
2026-03-03 Cvijic Christine Mikail President and CFO -$120,526.08 Transaction at $25.11, now +7.9%
2026-03-30 McMinn Rachel Chief Executive Officer -$73,995.065 Transaction at $22.07, now +22.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Neurogene Inc (NGNE) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for NGNE on Trend Edge →